Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.
Jian LiXinhua ZhangYanhong DengXin WuZhichao ZhengYongjian ZhouShirong CaiYanqiao ZhangJun ZhangKaixiong TaoYuehong CuiHui CaoKuntang ShenJiren YuYe ZhouWenxiao RenChenglin QuWanqi ZhaoJin HuWei WangJason YangLin ShenPublished in: The oncologist (2022)
Avapritinib was generally well tolerated and showed marked anti-tumor activity in Chinese patients with GIST bearing PDGFRA D842V mutations and notable efficacy as fourth- or later-line monotherapy (ClinicalTrials.gov Identifier: NCT04254939).